Clinical trials: Multiple Sclerosis-Relapsing-Remitting
Relapsing Remitting Multiple Sclerosis
How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
This study is to find out if starting at low dose Avonex and slowly increasing to full dose will improve flu like symptoms as a side effect of Avonex treatment.
- Trial name
- TODAY (NCT00574041)
- Testing
- Interferon beta-1a
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
General Note: throughout this record, "Rebif® New Formulation" is used for historical and consistency purposes. Objectives: Primary: To evaluate the efficacy of Rebif® New Formulation (Interferon-beta-1a [IFN-beta-1a], RNF)…
- Trial name
- IMPROVE (NCT00441103)
- Testing
- Rebif® New Formulation (IFN-beta-1a, RNF)
- Volunteers
- 180 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-Remitting Multiple Sclerosis
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt
The purpose of this observational study is to evaluate the Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients with Relapsing-Remitting Multiple Sclerosis in Egypt
- Trial name
- NCT05423769
- Testing
- Fingolimod
- Where
- 2 sites in Egypt
- Volunteers
- 30 people
- Sponsor
- Hikma Pharmaceuticals LLC
Multiple Sclerosis, Relapsing-Remitting
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.
- Trial name
- PRIVIG (NCT00220779)
- Testing
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 37 sites in United States, Austria and 10 more
- Volunteers
- 128 people
- Sponsor
- Grifols Therapeutics LLC
Relapsing Remitting Multiple Sclerosis (RRMS)
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.
- Trial name
- TOFIINGO (NCT01499667)
- Testing
- Fingolimod
- Where
- 44 sites in Australia, Austria and 9 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
The primary objective of the study is to assess the immunogenicity of Daclizumab High Yield Process (DAC HYP) 150 mg administered every 4 weeks by subcutaneous (SC) injection using the pre-filled syringe (PFS) in participants…
- Trial name
- OBSERVE (NCT01462318)
- Testing
- Midazolam, Caffeine, S-warfarin
- Where
- 19 sites in United States, Czechia and 2 more
- Volunteers
- 133 people
- Sponsor
- Biogen
Multiple Sclerosis
Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis
This research study is being done to evaluate the safety of BHT-3009 alone and when combined with atorvastatin (Lipitor) in patients with multiple sclerosis (MS).
- Trial name
- NCT00103974
- Testing
- BHT-3009-01
- Where
- 4 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Bayhill Therapeutics
Relapsing-remitting Multiple Sclerosis
Comparative Oral Bioavailability Study of MT-1303
The purpose of this study is to assess the comparative oral bioavailability of a Formulation B versus the Formulation A of MT-1303.
- Trial name
- NCT02310048
- Testing
- MT-1303-FormA, MT-1303-FormB
- Where
- United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Multiple Sclerosis, Relapsing-Remitting
BEYOND Pilot Study
The purpose of this study is to valuate safety and tolerability of Betaseron.
- Trial name
- NCT00893217
- Testing
- Betaseron (Interferon beta-1b, BAY86-5046)
- Where
- 14 sites in United States
- Volunteers
- 71 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing-Remitting
Study Evaluating CCI-779 in Relapsing Multiple Sclerosis
To evaluate the safety and tolerability of long-term therapy with 3 dose levels of oral CCI-779 administered to subjects with relapsing MS who completed study 3066A2-205-WW.
- Trial name
- NCT00228397
- Testing
- CCI-779
- Volunteers
- 221 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Multiple Sclerosis, Relapsing-Remitting
Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS
The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis (MS).
- Trial name
- CHANGE-MS (NCT02782858)
- Testing
- GNbAC1
- Where
- 12 sites in Bulgaria, Croatia and 10 more
- Volunteers
- 270 people
- Sponsor
- GeNeuro SA
Multiple Sclerosis, Relapsing Remitting
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients
This study is observational, non-controlled, multicentric and prospective, without experimental intervention or control. As part of the usual management of the subjects, scales will be used for the assessment of the spasticity…
- Trial name
- NCT01080040
- Where
- Argentina
- Volunteers
- 150 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
This is a multicenter study conducted in 3 parts. Part A is a double-blind placebo-controlled parallel-group period, and Part B and C are open-label extension periods.
- Conditions
- Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- MOTION - JAPAN (NCT01917019)
- Testing
- BIIB041 (fampridine)
- Where
- 19 sites in Japan
- Volunteers
- 101 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis (RRMS)
A Study for Tysabri Participant Preference
The primary objective of this study is to collect, evaluate and compare data on participant preference between subcutaneous (SC) and intravenous (IV) natalizumab.
- Trial name
- NCT05304520
- Testing
- Natalizumab
- Where
- 40 sites in Germany
- Volunteers
- 318 people
- Sponsor
- Biogen
Relapse-Remitting Multiple Sclerosis
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
This is a study to test if a new higher dose of Copaxone is more effective in treating relapsing-remitting multiple sclerosis than the currently available 20 mg dose.
- Trial name
- NCT00202982
- Testing
- glatiramer acetate 20 mg, glatiramer acetate 40 mg
- Where
- 20 sites in United States
- Volunteers
- 90 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
This was a multicenter, non-interventional, retrospective study aiming to evaluate the real-world effectiveness and safety of siponimod treatment in Chinese patients with relapsing forms of multiple sclerosis (RMS).
- Conditions
- Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06395909
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Novartis
Multiple Sclerosis
FOCUS Fatigue Outcome in Copaxone USers
The study primarily investigates the effect of copaxone on fatigue during treatment, compared to baseline in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT00267319
- Testing
- Glatiramer acetate
- Where
- Czechia
- Volunteers
- 111 people
- Sponsor
- Sanofi
Multiple Sclerosis
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
Primary Objective: To evaluate the efficacy, safety, and tolerability of alemtuzumab intravenously (IV) in pediatric participants from 10 to less than (<) 18 years of age with Relapsing Remitting Multiple Sclerosis (RRMS) who…
- Trial name
- LemKids (NCT03368664)
- Testing
- Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon
- Where
- 13 sites in France, Italy and 4 more
- Volunteers
- 16 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis, Relapsing-Remitting
Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis
The purpose of this study is to determine whether the use of EGb 761 by patients with Relapsing-Remitting Multiple Sclerosis is effective in improving cognition, when compared to placebo.
- Trial name
- NCT00276341
- Testing
- EGb 761® (Tanakan®)
- Where
- 30 sites in France
- Volunteers
- 47 people
- Sponsor
- Ipsen
Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis
Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) who are treated with dimethyl fumarate (DMF) as their…
- Trial name
- IMPROVE (NCT02323269)
- Testing
- dimethyl fumarate
- Where
- 10 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Biogen